TG Therapeutics, Inc. [NASDAQ: TGTX] dipped by -2.02% on the last trading session, reaching $15.31 price per share at the time. TG Therapeutics, Inc. represents 100.84M in outstanding shares, while the company has a total market value of $1.58B with the latest information.

The TG Therapeutics, Inc. traded at the price of $15.31 with 831958 shares were bought and sold during the latest trading session. Over the period of the last 3 months, the average trading volume of TGTX shares recorded 2.24M.

TG Therapeutics, Inc. [NASDAQ:TGTX]: Analyst Rating and Earnings

Its stock price has been found in the range of 4.59 to 16.22. This is compared to its latest closing price of $15.62.

Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on 03/05/2020.

Fundamental Analysis of TG Therapeutics, Inc. [TGTX]

Now let’s turn to look at profitability: with a current Operating Margin for TG Therapeutics, Inc. [TGTX] sitting at -114736.84.

This company’s Return on Total Capital is -382.36, and its Return on Invested Capital has reached -723.70%. Its Return on Equity is -381.16, and its Return on Assets is -191.70. These metrics suggest that this TG Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, TG Therapeutics, Inc. [TGTX] has generated a Total Debt to Total Equity ratio of 0.28. Similarly, its Total Debt to Total Capital is 0.28, while its Total Debt to Total Assets stands at 0.08.

What about valuation? This company’s Enterprise Value to EBITDA is -7.72. The Enterprise Value to Sales for this firm is now 8,855.45, and its Total Debt to Enterprise Value stands at 0.00. TG Therapeutics, Inc. [TGTX] has a Price to Book Ratio of 14.31.

Shifting the focus to workforce efficiency, TG Therapeutics, Inc. [TGTX] earns $1,448 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 1.49 and its Total Asset Turnover is 0.00. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.03 and its Current Ratio is 2.03. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

TG Therapeutics, Inc. [TGTX] has 100.84M shares outstanding, amounting to a total market cap of $1.58B. Its stock price has been found in the range of 4.59 to 16.22. At its current price, it has moved down by -5.64% from its 52-week high, and it has moved up 233.44% from its 52-week low.

This stock’s Beta value is currently 2.61, which indicates that it is 3.93% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 58.17. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is TG Therapeutics, Inc. [TGTX] a Reliable Buy?

Shares of TG Therapeutics, Inc. [TGTX], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.